Association of Phenotypic Age and Antibody Titers Among SARS-Co-V2 Infected Patients and Vaccinated Groups

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Defining the antibody response to SARS-CoV-2 will be essential for understanding disease progression, long-term immunity, and vaccine efficacy. Investigators designed a study investigating the neutralizing antibody response among post-infected and post-vaccinated individuals to determine how the spike protein neutralizing antibody correlates with natural infection and vaccination and how mutations of viral strains affect associated antibodies. New Taipei City Municipal TuCheng Hospital established a special infectious pneumonia ward in May 2021 to treat patients infected with symptomatic SARS-CoV-2 patients. During the period, 97 patients were admitted and enrolled. In light of the current timing of the pandemic, most published serological studies are predominantly cross-sectional or, at most, include a longitudinal follow-up. Cognitive function and PhenoAgeAccel will be examined for SARS-CoV-2 N and S titers decline trend analysis to correlate long-COVID brain fog or early decline of N and S antibodies.Therefore, investigators designed a three-year longitudinal study to detect patients' SARS-CoV-2 neutralizing and spike antibodies.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Healthy Volunteers: t
View:

• Age \> 20 yrs

• Evidenced COVID-19 infeciton by PCR sequening or commercial IVD rapid test kits. (stratified by infection periods, before 2022 vs. in 2022)

• Clealry understand the study protocol, blood drawing, organ function survey, phenoage and phenoageAccel exams and cognitive functional evaluation.

• Agree with regular follow-up as the protocol designs

Locations
Other Locations
Taiwan
TuCheng Hospital
RECRUITING
New Taipei City
Contact Information
Primary
Chia-Hsun Hsieh, PhD
wisdom5000@gmail.com
0975366137
Backup
Jeng-How Yang
summerfield8731113@gmail.com
0975366159
Time Frame
Start Date: 2022-06-01
Estimated Completion Date: 2025-11-30
Participants
Target number of participants: 330
Treatments
SARS-CoV-2 Infection
Participants from individuals with SARS-CoV-2 Infection .
SARS-CoV-2 non-infection with vaccination
Participants after the second dose covid19 vaccination from individuals without SARS-CoV-2 infection.
SARS-CoV-2 non-infection without vaccination
Participants get covid19 vaccination below 2 dose from individuals without SARS-CoV-2 infection.
Related Therapeutic Areas
Sponsors
Leads: Chang Gung Memorial Hospital

This content was sourced from clinicaltrials.gov